| http://www.w3.org/ns/prov#value | - Coombs' testing for patients with chronic lymphocytic leukemia, non-Hodgkin's lymphoma, or a history of autoimmune disease Assessment of endogenous erythropoietin (EPO) levels for patients with myelodysplastic syndromes (MDS) Consideration must be given to demonstrated risks of thromboembolism (see Recommendation IV), the possibility of death, and minimizing ESA use, particularly in patients with
|
